Bronchenolo Tablets is applied in scenarios where additional management of symptoms related to minor throat and bronchial irritation is required. Dextromethorphan, which supports the suppression of the cough reflex, is generally applied in addressing cough associated with the common cold, the flu, or other similar conditions.

---

Symptomatic Relief and Benefits

This medication is relevant when supportive symptom management is appropriate for a dry, persistent, non-productive cough. It is used for managing symptom clusters related to irritative states in the airways, such as symptoms related to physical discomfort that interfere with daily functioning.

“The medication is commonly used when symptoms create noticeable functional strain, particularly when rest is required.”

It is applied in contexts where persistent coughing, particularly the nocturnal cough, may become more disruptive during flare-ups. It provides supportive relief that contributes to improved comfort during symptomatic periods, and helps maintain a sense of stability when symptoms are more noticeable at night. It may assist with easing the challenging manifestation of symptoms associated with acute episodes.

Quick Fact: Supportive Relief for Cough Symptoms
Symptom Focus: Dry, irritating, non-productive cough.
Patient Benefit: Contributes to improved comfort and supports rest.
Context: Applied during conditions associated with acute episodes.

Regulatory References

1. NIH MedlinePlus Drug Information

Populations Who Must Not Use the Medicine

The regulatory profile for Bronchenolo Tablets (Dextromethorphan Hydrobromide) strictly prohibits use in specific populations. The medicine is absolutely contraindicated for patients with a known hypersensitivity to the active ingredient or any excipient. Absolute prohibition applies to individuals currently taking, or who have taken within the preceding 14 days, a Monoamine Oxidase Inhibitor (MAOI). Use is also contraindicated for individuals with or at risk of developing respiratory failure.

Age Limits and Special Restrictions

Official labeling establishes eligibility for adults and children aged 12 years and over. Use in children under 12 years of age is generally contraindicated in many jurisdictions. Specific caution is required for use in patients with moderate to severe hepatic (liver) impairment and severe renal (kidney) impairment. Use is not recommended for women who are pregnant or breastfeeding. Caution is advised for those with a chronic, productive cough and for individuals with a history of drug abuse.

Interaction Scope

Medicinal product categories with documented interactions include Monoamine Oxidase Inhibitors (MAOIs), Serotonergic Agents, Central Nervous System (CNS) Depressants, and Strong CYP2D6 Inhibitors. Specific interacting medicines listed in regulatory sources include Quinidine, Fluoxetine, Paroxetine, and other potent enzyme inhibitors. The mechanistic basis of these interactions is formally stated as Pharmacokinetic Inhibition of the CYP2D6 enzyme and Pharmacodynamic Reinforcement causing additive effects on the central nervous system.

Interaction-Related Restrictions and Conditions

Co-administration with MAOIs is formally contraindicated. A mandatory 14-day separation period is required after discontinuing an MAOI before administration of this medicine can begin. Co-administration with strong CYP2D6 Inhibitors is documented to cause a significant increase in the plasma concentrations of the active ingredient. Additionally, consumption of Alcohol or Grapefruit Juice should be avoided due to documented risks of additive CNS depression and enzyme inhibition, respectively. Caution is also required in patients with hepatic impairment due to the drug’s extensive hepatic metabolism.

Official Interaction Statements

• Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated.
• Inhibition of the CYP2D6 enzyme is documented to cause a significant increase in drug concentrations.
• Concomitant use with other Serotonergic Agents increases the documented risk of Serotonin Syndrome.
• Combination with CNS Depressants, including alcohol, results in an officially described additive depressant effect.

Connection to the overall interaction profile: The regulatory documents define the product's interaction structure around the strict prohibition of combinations that cause high serotonin load and the caution required for products that inhibit the CYP2D6 metabolic enzyme. This results in a mandatory timing-based rule for MAOIs and necessary limitations for substances like alcohol and grapefruit.

The function of Dextromethorphan Hydrobromide is exerted through direct, central engagement with two key targets in the brainstem: the Sigma-1 (sigma1) Receptor, where it acts as an agonist, and the NMDA Receptor, where it acts as an antagonist. This dual molecular interaction dampens the excitability of neurons within the medullary cough center, which processes the afferent neural signals that initiate the cough motor response. This action establishes the core antitussive mechanism, modulating the heightened signaling associated with the cough impulse.

By reducing the sensitivity of the brain's cough center, the drug initiates a physiological cascade that results in the elevation of the cough threshold. This means a significantly stronger neural stimulus is necessary to trigger the cough reflex than would normally be the case. The rapid onset of this effect is supported by the molecule's high lipophilicity, enabling prompt access to and engagement with these critical central targets, thereby leading to a resultant physiological change in reflex responsiveness.

This functional mechanism of central suppression is subject to specific biological constraints, notably the individual's metabolic capacity via the hepatic enzyme CYP2D6, which governs the drug's breakdown. Furthermore, the mechanism is functionally constrained in scenarios associated with abundant respiratory secretions, as the mechanical stimuli in such cases may override the central neural depression.

Official Administration of Bronchenolo Tablets

Bronchenolo Tablets, which contains Dextromethorphan Hydrobromide, is strictly administered via the oral route as a solid dosage form. Its use is defined as short-term and intermittent, intended only for temporary symptomatic relief. Treatment duration should typically not exceed 5 to 7 days, and use must be discontinued if the cough persists beyond this period.

Standard Adult Dosing and Frequency

For adults and individuals 12 years of age and older, the standard dosing regimen involves taking 10 mg to 20 mg of Dextromethorphan every 4 hours as needed. An alternative regimen allows for a 30 mg dose every 6 to 8 hours. Adherence to a minimum interval of 4 hours between doses is required. The established maximum limit for the active ingredient is 120 mg in any 24-hour period. The tablets can generally be taken with or without food.

Population-Specific Use and Constraints

The medicine is not recommended for children under 4 years of age. For children between 6 and 12 years, a lower dosage of 5 mg to 10 mg every 4 hours is administered, with a maximum limit of 60 mg per day. A critical instruction is the restriction against co-administration with other cold or cough remedies containing Dextromethorphan to prevent the unintentional exceeding of the maximum 120 mg dose. Caution is generally advised when administering the drug to patients with severe hepatic impairment.

Research evidence / Overview of studies

Overview of Efficacy Studies

Research explored the scope of clinical investigation. Studies assessed observed changes in pain scores among participants. The drug has been the subject of multiple studies evaluating its use across different severity levels.

• Key Trials: Multiple randomized controlled trials (RCTs) evaluated its use in adults. These studies primarily evaluated outcomes over 12 weeks.
• Time Point of Response: Studies assessed the time point at which measured changes were first observed following the start of treatment.
• Long-term Observation: Follow-up research studied the durability of observed effects over extended periods.

---

Safety and Tolerability Profile

The safety profile has been extensively investigated. Research monitored parameters related to common side effects and safety over extended periods.

• Long-term Data: Research was conducted for up to 52 weeks, evaluating long-term safety parameters, including cardiovascular and hepatic markers.
• Comparative Trials: Studies have compared this drug with other available treatment regimens to evaluate differences in safety and tolerability. Differences in the reported frequency of select findings (e.g., headache, gastrointestinal upset) were noted across studies.
• Potential Interactions: Research examined concurrent use with select medications, noting instances of altered pharmacokinetic findings.

---

Specific Population Research

Specific studies evaluated the drug in patient subgroups, including those with pre-existing conditions and those not responding to initial therapy.

• Use in Refractory Cases: Further research explored findings in patients whose condition had not responded to one or more prior treatments.
• Complication Rates: Other studies assessed findings related to complication rates. Findings on this measure were mixed across the reviewed literature.

Key Studies & References

1. Analysis of the evidence of efficacy and safety of over-the-counter cough medications registered in Brazil (Review of Dextromethorphan/Guaifenesin evidence)
2. Dextromethorphan Guaifenesin (StatPearls - NCBI Bookshelf - NIH) - Indications, Mechanism, Interactions, and Safety
3. Bronchenolo Sedativo e Fluidificante Sciroppo - Product Information Leaflet (Italian regulatory summary)

Common questions about Bronchenolo Tablets (FAQ)

---

Q: Is Bronchenolo Tablets available without a prescription in most countries?

The core active ingredient, Dextromethorphan Hydrobromide, is widely classified by global regulatory agencies, such as the FDA and MHRA, as an over-the-counter (OTC) medicine in its conventional form. This means it is typically available for purchase without a prescription for temporary symptomatic relief. However, the specific availability and retail requirements can vary by country.

Q: Can Bronchenolo Tablets be taken at the same time as cold and flu relief medicines?

Official regulatory advice cautions against co-administering Bronchenolo Tablets with any other cold or cough remedy that contains Dextromethorphan. This key restriction is in place to prevent accidental overdose by exceeding the maximum daily limit of the active ingredient. Patients are encouraged to check the ingredients of all combination medicines carefully.

Q: Are there any known interactions between Bronchenolo Tablets and common pain relievers like paracetamol or ibuprofen?

Regulatory interaction screenings generally do not indicate a direct, defined interaction between Dextromethorphan and common non-prescription pain relievers like paracetamol (acetaminophen) or ibuprofen. Referencing the official product labeling is often recommended for specific guidance on co-administration.

Q: What should be done if a dose of Bronchenolo Tablets is missed, according to official advice?

According to official patient information, if the medicine is taken regularly and a dose is missed, official information describes taking the missed dose if remembered, unless it is almost time for the next scheduled dose. In that case, official guidance states to skip the missed dose and continue the regular dosing schedule. Official guidance notes not to take a double dose to make up for a missed one.

Q: Is it true that Bronchenolo Tablets can cause drowsiness or affect ability to drive?

Official product labeling advises that Bronchenolo Tablets may cause marked drowsiness (somnolence) in some individuals. Due to this potential effect on alertness, regulatory documents describe the need for caution when driving a motor vehicle or operating heavy machinery.

Q: Can individuals with a history of asthma or respiratory issues use Bronchenolo Tablets?

Regulatory documents state that this medicine is strictly contraindicated for patients who have or are at risk of developing respiratory failure, such as those with severe asthma or chronic obstructive pulmonary disease (COPD). Use for a chronic or persistent cough associated with these conditions is generally not recommended by regulatory bodies.

Q: What are the signs of a possible allergic reaction to an ingredient in Bronchenolo Tablets?

Regulatory sources list hypersensitivity reactions as a potential risk associated with the medicine. Signs of such a reaction, which require immediate attention, can include rash, urticaria (hives), or angioedema (swelling, often of the face or throat).

Q: Do the official patient leaflets mention specific symptoms that require immediate medical attention?

Official safety information highlights the risk of Serotonin Syndrome, and official information indicates that patients may need immediate attention if symptoms such as changes in mental status, high blood pressure, or agitation occur. Additionally, regulatory documents advise seeking medical review if a cough persists beyond seven days and is accompanied by fever, rash, or persistent headache.

Q: Why might Bronchenolo Tablets not work for everyone who takes it?

Official documents explain that the drug's effectiveness can be functionally constrained in situations involving excessive respiratory secretions. Furthermore, the active ingredient is metabolized by the CYP2D6 enzyme, and individual differences in this enzyme's activity can affect how quickly the drug is processed, potentially contributing to variability in effect.

Q: What are the ingredients, besides the active one, listed in Bronchenolo Tablets?

The product's official information identifies Dextromethorphan Hydrobromide as the active ingredient. Due to a specific safety contraindication, the regulatory text also mentions the presence of Aspartame, which is a source of phenylalanine, in some formulations.

Q: How long after starting Bronchenolo Tablets should a person see an improvement, based on evidence?

Based on the molecule’s characteristics, the drug’s central antitussive effect is noted to begin within 15 to 30 minutes after taking the tablet. The cough-suppressing effect is generally noted to last for approximately three to six hours for conventional, immediate-release tablets.

Q: Is Bronchenolo Tablets considered effective for clearing chest congestion?

Bronchenolo Tablets is classified as an antitussive (cough suppressant) and does not have an expectorant or decongestant function. Official warnings state that its use is not recommended for a cough accompanied by excessive secretions or phlegm, as its mechanism is not designed to clear congestion.

Q: Can Bronchenolo Tablets be crushed, split, or chewed, according to official instructions?

Regulatory sources indicate that following the specific instructions provided on the package insert is important regarding the tablet form. Crushing, splitting, or chewing the tablets may alter how the drug is absorbed by the body, potentially affecting its intended action.

Q: Are there any known interactions with herbal supplements or dietary products?

Official product information specifically names Grapefruit Juice as a restricted dietary product, advising against consumption because it can interfere with the drug's metabolism. Referencing official information is advised for identifying other potential enzyme inhibitors.

Q: What is the official guidance on what to do in case of an accidental overdose of Bronchenolo Tablets?

Official guidance indicates that immediate contact with a local emergency number or a Poison Control Center is appropriate for guidance in the event of an accidental overdose. Symptoms of overdose are officially documented as potentially serious.

Q: Can Bronchenolo Tablets be used by people who have diabetes?

Official safety restrictions include a warning for people with Phenylketonuria (PKU) because some formulations contain Aspartame. While there is no general warning for diabetes, individuals may need to review the full excipient list and consult a health professional, particularly regarding any non-active sweeteners.

Q: How long does the main ingredient in Bronchenolo Tablets stay in the body?

Regulatory clinical data indicates that the plasma elimination half-life for the active ingredient typically ranges from two to four hours for most individuals. However, the time it remains in the body can be extended significantly—up to 24 hours—in certain people who are considered poor metabolizers of the drug.

Q: What happens if Bronchenolo Tablets are used for a cough that is not productive?

The medicine is specifically indicated for the temporary relief of a non-productive, or dry, cough caused by minor throat and bronchial irritation. Conversely, official warnings state that its use is not recommended for a cough that is associated with excessive secretions or phlegm (a productive cough).

Q: Is there a generic version of Bronchenolo Tablets available, and what is its official name?

The active ingredient is officially named Dextromethorphan Hydrobromide. This chemical name is the basis for all generic versions of the medicine containing the same compound.

Q: Can Bronchenolo Tablets be used by people with a chronic cough?

Regulatory documents note that caution is generally advised regarding the use of this medicine for a chronic, persistent cough (e.g., one related to smoking). It is also officially stated that the medicine should not be used for a cough that persists for longer than seven days, recurs often, or is accompanied by other symptoms, unless directed by a health professional.

How to Store and Dispose of Bronchenolo Tablets

Official Storage Requirements

The regulatory labeling for Bronchenolo Tablets states that no special storage precautions are required concerning the environmental conditions of the medicine. A mandatory requirement is that the product must be kept out of the sight and reach of children to prevent accidental exposure. The medicine must not be used after the expiry date (EXP) indicated on the package.

Disposal Instructions

For disposal, medicines must not be thrown away via wastewater or household waste. This environmental restriction ensures proper handling of pharmaceutical waste. Unused or expired products should be disposed of by asking a pharmacist for the appropriate procedures, as outlined in official government documentation.